Which has preferable valuation & earnings, HELP or PALI?

Palisade Bio has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Palisade Bio $250K 1,031.68 -$16.78M -$0.48 N/A

Is HELP or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Palisade Bio N/A -33.47% -31.79%

Does the media prefer HELP or PALI?

In the previous week, Cybin had 6 more articles in the media than Palisade Bio. MarketBeat recorded 9 mentions for Cybin and 3 mentions for Palisade Bio. Cybin's average media sentiment score of 1.04 beat Palisade Bio's score of 0.47 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or SPTX more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Seaport Therapeutics N/A N/A N/A

Does the media refer more to PALI or SPTX?

In the previous week, Seaport Therapeutics had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Seaport Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Seaport Therapeutics' score of 0.38 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seaport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is SGP or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% Palisade Bio N/A -33.47% -31.79%

Does the media prefer SGP or PALI?

In the previous week, Spyglass Pharma had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Spyglass Pharma and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Spyglass Pharma's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PALI or ARDX?

Palisade Bio has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,031.68 -$16.78M -$0.48 N/A Ardelyx $407.32M 1.99 -$61.60M -$0.22 N/A

Is PALI or ARDX more profitable?

Palisade Bio has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Palisade Bio's return on equity of -33.47% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Ardelyx -12.35% -36.00% -10.77%

Does the media prefer PALI or ARDX?

In the previous week, Ardelyx had 19 more articles in the media than Palisade Bio. MarketBeat recorded 22 mentions for Ardelyx and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Ardelyx's score of -0.01 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Palisade Bio (PALI) Competitors

$1.45 -0.03 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.05 (+3.79%)

As of 06:37 PM Eastern

Compare

PALI vs. HELP, SPTX, TBPH, SGP, and ARDX

Should you buy Palisade Bio stock or one of its competitors? Palisade Bio's main competitors and comparable companies include Cybin (HELP), Seaport Therapeutics (SPTX), Theravance Biopharma (TBPH), Spyglass Pharma (SGP), and Ardelyx (ARDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Palisade Bio compare to Cybin?

Cybin (NASDAQ:HELP) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Palisade Bio has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Palisade Bio	N/A	-33.47%	-31.79%

Cybin has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

In the previous week, Cybin had 6 more articles in the media than Palisade Bio. MarketBeat recorded 9 mentions for Cybin and 3 mentions for Palisade Bio. Cybin's average media sentiment score of 1.04 beat Palisade Bio's score of 0.47 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cybin presently has a consensus price target of $46.33, suggesting a potential upside of 340.85%. Palisade Bio has a consensus price target of $9.83, suggesting a potential upside of 564.41%. Given Palisade Bio's higher probable upside, analysts plainly believe Palisade Bio is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

17.9% of Cybin shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Palisade Bio beats Cybin on 10 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Seaport Therapeutics?

Palisade Bio (NASDAQ:PALI) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Palisade Bio currently has a consensus price target of $9.83, indicating a potential upside of 564.41%. Seaport Therapeutics has a consensus price target of $38.57, indicating a potential upside of 115.12%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Seaport Therapeutics	N/A	N/A	N/A

In the previous week, Seaport Therapeutics had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Seaport Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Seaport Therapeutics' score of 0.38 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seaport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Palisade Bio has higher revenue and earnings than Seaport Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Palisade Bio beats Seaport Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Theravance Biopharma?

Palisade Bio (NASDAQ:PALI) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Palisade Bio presently has a consensus price target of $9.83, indicating a potential upside of 564.41%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

Palisade Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Theravance Biopharma has a net margin of 51.58% compared to Palisade Bio's net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Theravance Biopharma	51.58%	-0.77%	-0.46%

In the previous week, Palisade Bio had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Palisade Bio and 0 mentions for Theravance Biopharma. Palisade Bio's average media sentiment score of 0.47 beat Theravance Biopharma's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Palisade Bio	Neutral
Theravance Biopharma	Neutral

Summary

Theravance Biopharma beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Palisade Bio's return on equity of -33.47% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Palisade Bio	N/A	-33.47%	-31.79%

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spyglass Pharma currently has a consensus target price of $44.00, indicating a potential upside of 84.10%. Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 564.41%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A

In the previous week, Spyglass Pharma had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Spyglass Pharma and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Spyglass Pharma's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palisade Bio beats Spyglass Pharma on 11 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Ardelyx?

Palisade Bio (NASDAQ:PALI) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Palisade Bio has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A
Ardelyx	$407.32M	1.99	-$61.60M	-$0.22	N/A

In the previous week, Ardelyx had 19 more articles in the media than Palisade Bio. MarketBeat recorded 22 mentions for Ardelyx and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.47 beat Ardelyx's score of -0.01 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Palisade Bio has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Palisade Bio's return on equity of -33.47% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Ardelyx	-12.35%	-36.00%	-10.77%

Palisade Bio currently has a consensus target price of $9.83, suggesting a potential upside of 564.41%. Ardelyx has a consensus target price of $13.90, suggesting a potential upside of 326.38%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Palisade Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Summary

Palisade Bio beats Ardelyx on 10 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$252.69M	$12.25B	$7.14B	$13.21B
Dividend Yield	N/A	2.65%	2.53%	16.47%
P/E Ratio	-3.02	802.39	275.15	25.94
Price / Sales	1,010.77	747.53	566.79	83.59
Price / Cash	N/A	86.04	77.41	52.81
Price / Book	1.67	10.66	10.80	6.27
Net Income	-$16.78M	$2.83B	$3.50B	$382.13M
7 Day Performance	1.40%	-1.62%	-2.02%	-1.35%
1 Month Performance	-34.09%	-7.65%	-7.53%	-5.60%
1 Year Performance	-27.50%	-6.26%	3.32%	-1.54%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	3.0691 of 5 stars	$1.45 -2.0%	$9.83 +578.2%	-11.9%	$252.69M	$250K	N/A	14	Analyst Forecast
HELP Cybin	4.4316 of 5 stars	$12.70 +0.9%	$46.33 +264.8%	N/A	$1.00B	N/A	N/A	100
SPTX Seaport Therapeutics	2.9607 of 5 stars	$18.69 -4.8%	$38.57 +106.4%	N/A	$1.00B	N/A	N/A	58	News Coverage Positive News Analyst Forecast
TBPH Theravance Biopharma	1.5879 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	90
SGP Spyglass Pharma	1.8753 of 5 stars	$25.44 -2.1%	$44.00 +73.0%	N/A	$850.46M	N/A	N/A	65	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. HELP, SPTX, TBPH, SGP, and ARDX

How does Palisade Bio compare to Cybin?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Summary

How does Palisade Bio compare to Theravance Biopharma?

Summary

How does Palisade Bio compare to Spyglass Pharma?

Summary

How does Palisade Bio compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. HELP, SPTX, TBPH, SGP, and ARDX

How does Palisade Bio compare to Cybin?

Which has preferable valuation & earnings, HELP or PALI?

Is HELP or PALI more profitable?

Which has more risk and volatility, HELP or PALI?

Does the media prefer HELP or PALI?

Do analysts rate HELP or PALI?

Do insiders and institutionals hold more shares of HELP or PALI?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Do analysts prefer PALI or SPTX?

Is PALI or SPTX more profitable?

Does the media refer more to PALI or SPTX?

Which has better earnings and valuation, PALI or SPTX?

Do institutionals & insiders believe in PALI or SPTX?

Summary

How does Palisade Bio compare to Theravance Biopharma?

Do analysts prefer PALI or TBPH?

Which has better earnings & valuation, PALI or TBPH?

Which has more risk & volatility, PALI or TBPH?

Do institutionals & insiders believe in PALI or TBPH?

Is PALI or TBPH more profitable?

Does the media prefer PALI or TBPH?

Summary

How does Palisade Bio compare to Spyglass Pharma?

Is SGP or PALI more profitable?

Do institutionals & insiders have more ownership in SGP or PALI?

Do analysts rate SGP or PALI?

Which has higher earnings & valuation, SGP or PALI?

Does the media prefer SGP or PALI?

Summary

How does Palisade Bio compare to Ardelyx?

Which has better earnings & valuation, PALI or ARDX?

Does the media prefer PALI or ARDX?

Is PALI or ARDX more profitable?

Do analysts prefer PALI or ARDX?

Do insiders and institutionals have more ownership in PALI or ARDX?

Which has more risk & volatility, PALI or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools